(Q40020098)

16 September 2017

Low-dose metronomic cyclophosphamide treatment mediates ischemia-dependent K-ras mutation in colorectal carcinoma xenografts (English)

1 reference

16 September 2017

1 reference

1 reference

S Shahrzad

1

1 reference

16 September 2017

S Shirasawa

2

1 reference

16 September 2017

T Sasazuki

3

1 reference

16 September 2017

J W Rak

4

1 reference

16 September 2017

B L Coomber

5

1 reference

16 September 2017

language of work or name

English

0 references

publication date

28 January 2008

1 reference

16 September 2017

1 reference

16 September 2017

27

1 reference

16 September 2017

3729-3738

1 reference

16 September 2017

26

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1211031

16 September 2017

0 references

cites work

Cancer risk in mutation carriers of DNA-mismatch-repair genes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Hypoxic cytotoxic agents: a new approach to cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Exploiting tumour hypoxia in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Probing immune functions in RAG-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

What Is the Evidence That Tumors Are Angiogenesis Dependent?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Angiogenic inhibitors: a new therapeutic strategy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Hypoxia in head and neck cancer: how much, how important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Replication errors: cha(lle)nging the genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Predicting benefit from anti-angiogenic agents in malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Clinical translation of angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Mismatch repair genes hMLH1 and hMSH2 and colorectal cancer: a HuGE review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Mutations associated with HNPCC predisposition -- Update of ICG-HNPCC/INSiGHT mutation database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Control of oncogenesis and cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Fluctuating and diffusion-limited hypoxia in hypoxia-induced metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Ischemia-induced K-ras mutations in human colorectal cancer cells: role of microenvironmental regulation of MSH2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Altered growth of human colon cancer cell lines disrupted at activated Ki-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Heterogeneous vascular dependence of tumor cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

NMR spectroscopic studies of intermediary metabolites of cyclophosphamide. A comprehensive kinetic analysis of the interconversion of cis- and trans-4-hydroxycyclophosphamide with aldophosphamide and the concomitant partitioning of aldophosphamide b

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Microsatellite instability analysis and/or immunostaining for the diagnosis of hereditary nonpolyposis colorectal cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

Heterogeneity of cancer cells from a single human colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

7 January 2021

Cancer vascularization: implications in radiotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

7 January 2021

Cyclophosphamide metabolites and their related compounds. 2. Preparation of an active species of cyclophosphamide and related compounds

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

7 January 2021

Mutagenesis induced by the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1211031

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1211031

1 reference

Dimensions Publication ID

16 September 2017

0 references

1 reference